A look ahead

Yes the diabetes device world is still buzzing about the approval of Dexcom’s (NASDAQ: DXCM) G6 system and money continues to flow into the space as evidenced by Bigfoot’s latest funding round. Equally exciting is the buzz surrounding just how impactful all these new way cool whiz bang insulin dosing algorithms are becoming. While it may have seemed like a pipe dream only a few short years ago it is now possible to imagine a world when patients will not just have a closed loop insulin delivery system but one that does not require a patient to count . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.